Skip to main content


Cancer & Metabolism accepted for inclusion in SCIE

We are delighted to announce that Cancer & Metabolism has been accepted for inclusion in Science Citation Index Expanded (SCIE), a key database of Web of Science, published by Clarivate Analytics. Starting 2020, Cancer & Metabolism  will be published in the annual Journal Citation Reports, at which point it will receive the associated journal metrics, such as Immediacy Index, Eigenfactor Score, and Journal Impact Factor.

We would like to thank everyone for supporting Cancer & Metabolism  and contributing to this success. 

Impact of COVID-19

COVID-19 © elipe Esquivel Reed, used under Creative Commons Attribution-Share Alike 4.0 license

As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our usual peer review process. We thank referees for their continued support in these challenging times and ask authors for their patience and understanding.

Thumbnail image by Felipe Esquivel Reed, used under Creative Commons Attribution-Share Alike 4.0 license.

New Reviewer Recruitment

Cancer & Metabolism invites you to join our team of reviewers. For consideration, please send your CV with keywords and expertise to

Featured article: Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC

Tronstad et al. investigated the role the role of succinate dehydrogenase in relation to Epithelial to mesenchymal transition (EMT) in breast cancer progression and therapy.

Editorial Board

Dr. Michael Pollak, co-Editor-in-Chief

Dr. Pollak is an internationally recognized expert in cancer endocrinology at the Lady Davis Institute for Medical Research of McGill University and a clinical oncologist at the Jewish General Hospital, Quebec, Canada.

"Cancer & Metabolism will provide a forum for rapid dissemination of research findings concerning metabolic factors that influence cancer risk and cancer pathophysiology, and cancer treatment. The scope of the Journal will allow for an interdisciplinary readership including cancer biologists, endocrinologists, oncologists, clinical trialists and population scientists."

New Content ItemDr. Matthew G. Vander Heiden, co-Editor-in-Chief

Dr. Vander Heiden is Associate Director at the Koch Institute for Integrative Cancer Research at MIT. Extensively published in over 140 peer reviewed articles and book chapters, his research interests focus on the metabolic processes of cancer cells, including how glucose metabolism affects tumor growth and how these studies may lead to new developments in targeted cancer therapy. A renowned innovative researcher in his field, Dr. Vander Heiden received the 2017 Philip A. Sharp Innovation in Collaboration Award from Stand Up to Cancer (SU2C).

Editorial Board Members

Abass AlaviUniversity of Pennsylvania School of Medicine, USA 
Lewis CantleyWeill Cornell Medical College, USA 
Peter CarmelietVesalius Research Center, Belgium 
Ralph DeBerardinisUniversity of Texas Southwestern Medical Center, USA 
Teresa FanMarkey Cancer Center, USA 
Robert GatenbyH. Lee Moffitt Cancer Center and Research Institute, USA 
Kun-Liang GuanUniversity of  California, San Diego,
Rudolf KaaksGerman Cancer Research Center, Germany 
Andrew LaneMarkey Cancer Center, USA 
Gordon MillsUniversity of Texas M. D. Anderson Cancer Center, USA 
Lorenz Poellinger, Karolinska Institute, Sweden 
Jacques Pouyssegur, Institute of Research on Cancer and Aging, France 
Joshua Rabinowitz, Princeton University, USA
Peter RatcliffeNuffield Department of Clinical Medicine, UK 

Jeffrey Rathmell, Duke University, USA 
Jared RutterUniversity of Utah School of Medicine, USA 
David SabatiniWhitehead Institute for Biomedical Research, USA 
Paolo Sassone-CorsiUniversity of California, Irvine, USA
Gregg SemenzaJohns Hopkins University School of Medicine, USA 
Celeste SimonUniversity of Pennsylvania School of Medicine, USA 
Alexei VazquezThe Cancer Institute of New Jersey, USA 
Bert Vogelstein, Johns Hopkins University School of Medicine, USA 
Karen VousdenBeatson Institute for Cancer Research, UK 
Kathryn WellenUniversity of Pennsylvania, USA
Eileen WhiteThe Cancer Institute of New Jersey, USA 
Yue XiongUniversity of North Carolina, Chapel Hill, USA 

Chi Van Dang, Editor Emeritus

Chi Dang is a professor, physician-researcher, renowned cancer biologist and hematologist-oncologist, who serves as director of the Abramson Cancer Center at the University of Pennsylvania.

"After several decades of profound advances in our understanding of the genetics and molecular biology of cancer, it has become self-evident that metabolism and bioenergetics are regulated by cancer genes and are intimately linked to the growth and survival of cancer cells. The obesity pandemic connected to increased cancer risk further underscore the importance of a richer understanding of cancer and organismal metabolism. In this regard, Cancer & Metabolism is launched uniquely to fulfill the needs of a burgeoning field which is at the crossroads of many scientific disciplines."


Efficient peer review

We recognize that scientifically sound, high-quality manuscripts often receive negative decisions from high-impact journals on the basis of perceived general interest levels or the absence of extensive mechanisms supporting research hypotheses. As a niche journal, Cancer & Metabolism will consider rapid publication of such manuscripts if they are submitted together with the original peer reviewer reports, letter of rejection, and a brief rebuttal.


Annual Journal Metrics

  • Speed
    65 days to first decision for reviewed manuscripts only
    59 days to first decision for all manuscripts
    135 days from submission to acceptance
    35 days from acceptance to publication

    Citation Impact
    1.886 - Source Normalized Impact per Paper (SNIP)
    3.928 - SCImago Journal Rank (SJR) 

    210 Altmetric Mentions